Structure Therapeutics Inc. (GPCR)

Structure Therapeutics Inc. ($GPCR) sees social dominance surge 343% amid mixed sentiment. Investors weigh positive price action and development potential against competitive pressures and licensing deal concerns.

About Structure Therapeutics Inc.

Structure Therapeutics Inc. is a pharmaceutical company focused on developing novel therapeutics for metabolic diseases.
Structure Therapeutics Inc. uses the ticker $GPCR for trading. Listed in the Stocks category within the Healthcare sectors.

Insights

Structure Therapeutics Inc. (GPCR) social dominance is up 1427.91% from the previous week.
Structure Therapeutics Inc. (GPCR) Galaxy Score™ is up 11.9% from the previous week.

Price: $70.10

Price 24-Hour Time-Series Raw Data
The current price action for $GPCR is influenced by positive trading interest and analyst upgrades, but tempered by concerns over competition and licensing agreements. Recent social posts highlight significant surges and volume, indicating strong short-term trading interest.

24-Hour: -2.82% 7-Day: -7.19% 30-Day: -20.95%

1-Year High: $93.80 on 2026-01-21
1-Year Low: $16.20 on 2025-08-07

AltRank: [-----]

AltRank Line Chart
AltRank 24-Hour Time-Series Raw Data
Structure Therapeutics Inc. (GPCR) is currently AltRank #1,109 based on combined combined social and market metrics Daily Average: [---]
[--] Week: [-----] [----]
1-Year High: [-----] on 2026-02-09
1-Year Low: [---] on 2026-01-25

Galaxy Score: [-----]

Galaxy Score Line Chart
Galaxy Score 24-Hour Time-Series Raw Data
Current Value: [-----]
Daily Average: [--]
[--] Week: [--] +5
[--] Month: [--] +5
[--] Months: [--] +11
[--] Year: [--] [---]
1-Year High: [--] on 2026-01-30
1-Year Low: [--] on 2025-10-25

Engagements: [-----] (24h)

Engagements Line Chart
Engagements 24-Hour Time-Series Raw Data
Current Value: [-----]
Daily Average: [------]
[--] Week: [------] -71%
[--] Month: [-------] -54%
[--] Months: [---------] +51%
[--] Year: [---------] -0.20%
1-Year High: [-------] on 2025-12-08
1-Year Low: [---] on 2025-09-14

Engagements by network (24h): YouTube: [--] TikTok: [--] News: [--] X: [-----] Reddit: [--]

Mentions: [---] (24h)

Mentions Line Chart
Mentions 24-Hour Time-Series Raw Data
Current Value: [---]
Daily Average: [--]
[--] Week: [---] -16%
[--] Month: [---] +473%
1-Year High: [---] on 2025-12-08
1-Year Low: [--] on 2025-09-14

Mentions by network (24h): YouTube: [--] TikTok: [--] News: [--] X: [---] Reddit: [--]

Creators: [--] (24h)

Creators Line Chart
Creators 24-Hour Time-Series Raw Data
[--] unique social accounts have posts mentioning Structure Therapeutics Inc. (GPCR) in the last [--] hours which is down 16% from [--] in the previous [--] hours Daily Average: [--]
[--] Week: [---] -8.80%
[--] Month: [---] +421%
1-Year High: [---] on 2025-12-08
1-Year Low: [--] on 2025-09-14

The most influential creators that mention Structure Therapeutics Inc. in the last [--] hours

Creator	Rank	Followers	Posts	Engagements
@Pharmdca	[--]	[-------]	[--]	[---]
@semodough	[--]	[-----]	[--]	[---]
@cloud_walker200	[--]	[---]	[--]	[---]
@MeadowCapital	[--]	[-----]	[--]	[--]
@PCM_bio	[--]	[-----]	[--]	[--]
@JoseRestonVA	[--]	[-----]	[--]	[--]
@Quantumup1	[--]	[-----]	[--]	[--]
@felandostephen1	[--]	[---]	[--]	[--]
@PersimmonTI	[--]	[------]	[--]	[--]
@doepke_michel	[--]	[-----]	[--]	[--]

Sentiment: 79%

Sentiment Line Chart
Sentiment 24-Hour Time-Series Raw Data
Current Value: 79%
Daily Average: 75%
[--] Week: 62% -38%
[--] Month: 69% -18%
[--] Months: 69% +9%
[--] Year: 69% -11%
1-Year High: 100% on 2025-05-31
1-Year Low: 35% on 2025-08-08

Most Supportive Themes:

Positive Price Action and Trading Interest: (40%) Multiple posts highlight $GPCR's ascents, jumps, and spikes, indicating positive price movement and attracting trading interest.
Partnership and Development Potential: (30%) Discussions mention potential partnerships, particularly with Amgen, and the development of novel therapeutics for metabolic diseases, suggesting future growth prospects.
Inclusion in Investment Watchlists and ETFs: (30%) $GPCR is frequently listed in trading watchlists and identified as a holding in the Roundhill GLP-1 & Weight Loss ETF, indicating investor interest.

Most Critical Themes:

Competition and Market Uncertainty: (60%) The success of competitors like $NVO and $LLY in the oral incretin space creates market uncertainty and competitive pressure for $GPCR.
Licensing Agreement Concerns: (40%) A recent licensing agreement with Genentech was noted as not being the large pharma partnership some investors were anticipating, leading to some disappointment.

Social Dominance: 0.00812%

Social Dominance Line Chart
Social Dominance 24-Hour Time-Series Raw Data
Current Value: 0.00812%
Daily Average: 0.013%
[--] Week: 0.066% +0.061%
[--] Month: 0.02% -0.01%
[--] Months: 0.02% -0.028%
[--] Year: 0.02% +0.011%
1-Year High: 0.075% on 2025-12-08
1-Year Low: 0.0012% on 2025-09-14

Market Dominance: 0.00561%

Market Dominance Line Chart
Market Dominance 24-Hour Time-Series Raw Data
Current Value: 0.00561%
Daily Average: 0%
1-Year High: 0.00776% on 2026-01-21
1-Year Low: 0.00561% on 2026-02-16

Market Cap: $4,949,687,202

Market Cap Line Chart
Market Cap 24-Hour Time-Series Raw Data
Current Value: $4,949,687,202
Daily Average: $5,870,882,631
[--] Week: $4,980,062,049 -6%
[--] Month: $4,949,687,202 -21%
1-Year High: $6,625,248,505 on 2026-01-21
1-Year Low: $4,949,687,202 on 2026-02-13

Top Structure Therapeutics Inc. Social Posts

Top posts by engagements in the last [--] hours

Showing a maximum of [--] top social posts without a LunarCrush subscription.

"$LLY $NVO How switch from injections to pills is expanding big pharmas hopes Pills could make treatment more mainstream with GLP-1 sector predicted to be worth $200bn by end of the decade $XBI $VKTX $AMGN $GPCR $MRK $PFE https://www.theguardian.com/science/2026/feb/15/weight-loss-race-injections-pills-big-pharma https://www.theguardian.com/science/2026/feb/15/weight-loss-race-injections-pills-big-pharma"
X Link @WallStSai 2026-02-15T19:00Z [----] followers, [----] engagements

"@mark1eddie @cloud_walker200 $AMGN top obesity M&A candidate. They hinted they wanted oral long ago Question if they think MariTide is competitive at all For oral would they spend $10 B on $GPCR a drug that could fail I dont know. I dont envy their position as they are all in"
X Link @bioinvestor24 2026-02-15T18:32Z [----] followers, [---] engagements

"another overhaul is market perceives oral small molecule to be much more favored by MNC over oral peptides (hence $gpcr market cap $5B) bc it's easy to make and sell without the fasting requirement. There's a concern that others are afraid to deploy capex like $lly does to build peptide plants in order to scale https://twitter.com/i/web/status/2023059613344813108 https://twitter.com/i/web/status/2023059613344813108"
X Link @cloud_walker200 2026-02-15T15:39Z [---] followers, [---] engagements

"LT position into [----] Part [--] # [--] Portfolio Pick Buyouts $RNA $NARI $BPMC $MYOV $IMGN $KRTX $HZNP $PRVB $ISEE $BLU $CTIC $FSTX $ICVX $LVGO $STML $JUNO $CMRX $RLYP $ITCI $KVUE Tech positions in order- $AMZN $TSLA $SOFI $COIN $GOOG $NVDA $AMD $RBRK $META $NFLX $UBER $MSFT $AVGO $ZS $MELI $IREN $NBIS Top Biotech positions: $VKTX $CYTK $BBIO $TMDX $MDGL $HROW $SLNO $IMNM $GPCR $OCUL $CRVS https://twitter.com/i/web/status/2002067407834374356 https://twitter.com/i/web/status/2002067407834374356"
X Link @Pharmdca 2025-12-19T17:24Z 108.6K followers, 56.4K engagements

Limited data mode. Full metrics available with subscription: lunarcrush.com/pricing